Table 1.
Baseline characteristics.
| Characteristics | D-TACE group (N = 293) | D-TACE + lipiodolgroup (N = 34) | P value |
|---|---|---|---|
| (No, %; mean ± SD) | (No, %; mean ± SD) | ||
| Gender | |||
| Male | 243 (82.9%) | 30 (88.2%) | 0.431 |
| Female | 50 (17.1%) | 4 (11.8%) | |
| Age (years) | 56.9 ± 11.1 | 55.0 ± 11.8 | 0.353 |
| BCLC class | |||
| A | 81 (27.6%) | 12 (35.3%) | 0.572 |
| B | 75 (25.6%) | 9 (26.5%) | |
| C | 137 (46.8%) | 13 (38.2%) | |
| Hepatitis | |||
| Hepatitis B | 221 (75.4%) | 27 (79.4%) | 0.607 |
| Other | 72 (24.6%) | 7 (20.6%) | |
| Child-pugh score | |||
| A | 239 (81.6%) | 30 (88.2%) | 0.335 |
| B | 54 (18.4%) | 4 (11.8%) | |
| B7 | 49 | 2 | |
| B8 | 4 | 1 | |
| B9 | 1 | 1 | |
| TB (µmol/L) | 21.0 ± 14.1 | 17.9 ± 7.1 | 0.198 |
| Albumin (g/L) | 35.4 ± 6.1 | 36.3 ± 5.6 | 0.422 |
| PT (s) | 14.1 ± 1.5 | 14.2 ± 1.6 | 0.584 |
| AST (µmol/L) | 78.5 ± 100.3 | 88.0 ± 99.8 | 0.602 |
| ALT (µmol/L) | 60.8 ± 99.7 | 63.3 ± 47.5 | 0.889 |
| PLR | 150.6 ± 98.1 | 133.9 ± 72.7 | 0.338 |
| NLR | 4.3 ± 6.6 | 3.3 ± 2.0 | 0.347 |
| Tumor size (cm) | 8.0 ± 4.3 | 9.5 ± 4.9 | 0.08 |
| Tumor number | |||
| ≤3 | 291 (99.3%) | 33 (97.1%) | 0.191 |
| >3 | 2 (0.7%) | 1 (2.9%) | |
| α-Fetoprotein level | |||
| >400 ng/mL | 122 (41.6%) | 18 (52.9%) | 0.207 |
| ≤400 ng/ml | 171 (58.4%) | 16 (47.1%) | |
| Ascites | |||
| Absent | 246 (84.0%) | 30 (88.2%) | 0.515 |
| Present | 47 (16.0%) | 4 (11.8%) | |
| TACE sessions | 3.45 ± 2.2 | 3.91 ± 2.2 | 0.238 |
Note. D-TACE: drug-elutingbeads-transcatheter arterial chemoembolization; SD: standard deviation; BCLC: barcelona clinical liver cancer; TB: total bilirubin; PT: prothrombin time; AST: aspartate aminotransferase; ALT: alanine aminotransferase; PLR: platelet-to-lymphocyte ratio; NLR: neutrophil-to-lymphocyte ratio.